Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2019 Filed Apr 30, 2019 21:16 UTC |
LIDDY EDWARD MDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005305 · edgar.xml · nonDerivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,153 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:18 UTC |
Alpern Robert JDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005307 · edgar.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,406 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:17 UTC |
STARKS DANIEL JDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005306 · edgar.xml · nonDerivative · entry 1 STARKS DANIEL J · CIK 0000902132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,018,425 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:19 UTC |
AUSTIN ROXANNE SDirector
|
GrantOption (right to buy) · Derivative | 11,683 | $0.00 Strike: $78.06 | $0.00 |
DisclosureSEC source: 0001179110-19-005308 · edgar.xml · derivative · entry 2 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,683 Underlying: Common shares · 11,683 shares Expires 2029-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:19 UTC |
AUSTIN ROXANNE SDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005308 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,913 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:20 UTC |
Blount Sally E.Director
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005309 · edgar.xml · nonDerivative · entry 1 Blount Sally E. · CIK 0001537286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,766 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:22 UTC |
SCOTT SAMUEL C IIIDirector
|
GrantOption (right to buy) · Derivative | 10,146 | $0.00 Strike: $78.06 | $0.00 |
DisclosureSEC source: 0001179110-19-005310 · edgar.xml · derivative · entry 2 SCOTT SAMUEL C III · CIK 0001202862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,146 Underlying: Common shares · 10,146 shares Expires 2029-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:22 UTC |
SCOTT SAMUEL C IIIDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005310 · edgar.xml · nonDerivative · entry 1 SCOTT SAMUEL C III · CIK 0001202862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,053 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:23 UTC |
OSBORN WILLIAM ADirector
|
GrantOption (right to buy) · Derivative | 11,990 | $0.00 Strike: $78.06 | $0.00 |
DisclosureSEC source: 0001179110-19-005311 · edgar.xml · derivative · entry 2 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,990 Underlying: Common shares · 11,990 shares Expires 2029-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:23 UTC |
OSBORN WILLIAM ADirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005311 · edgar.xml · nonDerivative · entry 1 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,323 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:24 UTC |
Stratton John GDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005312 · edgar.xml · nonDerivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,641 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 36,716 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · derivative · entry 12 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,430 Underlying: Common shares · 36,716 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 46,016 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · derivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,016 Underlying: Common shares · 46,016 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 12,332 | $70.02 | $863,486.64 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,706 Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 70,400 | $70.00 | $4,928,000.00 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,038 Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 36,716 | $59.94 | $2,200,757.04 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 46,016 | $44.40 | $2,043,110.40 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 56,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005147 · edgar.xml · derivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,227 Underlying: Common shares · 56,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
SaleCommon shares without par value | 56,000 | $76.00 | $4,256,000.00 |
DisclosureSEC source: 0001179110-19-005147 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,935 Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 21:10 UTC |
Fussell Stephen RExecutive Vice President
|
Exercise / conversionCommon shares without par value | 56,000 | $47.00 | $2,632,000.00 |
DisclosureSEC source: 0001179110-19-005147 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 21:05 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
PurchaseCommon shares without par value | 2,000 | $73.40 | $146,798.20 |
DisclosureSEC source: 0001179110-19-005145 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,562 Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 21:06 UTC |
Contreras JaimeSenior Vice President
|
SaleCommon shares without par value | 918 | $73.12 | $67,124.16 |
DisclosureSEC source: 0001179110-19-005146 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,227 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:04 UTC |
LANE ANDREW HExecutive Vice President
|
Tax withholdingCommon shares without par value | 365 | $79.94 | $29,178.10 |
DisclosureSEC source: 0001179110-19-004523 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,932 Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 21:04 UTC |
LANE ANDREW HExecutive Vice President
|
GrantCommon shares without par value | 1,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004523 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,297 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:16 UTC |
Scoggins Christopher JSenior Vice President
|
GrantOption (right to buy) · Derivative | 43,388 | $79.98 Strike: $79.98 | $3,470,172.24 |
DisclosureSEC source: 0001179110-19-004719 · edgar.xml · derivative · entry 2 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,388 Underlying: Common shares · 43,388 shares Expires 2029-03-31 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,462 on April 1, 2020, 14,463 on April 1, 2021, and 14,463 on April 1, 2022. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:16 UTC |
Scoggins Christopher JSenior Vice President
|
GrantCommon shares without par value | 8,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004719 · edgar.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,578 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:24 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
GrantOption (right to buy) · Derivative | 43,388 | $79.98 Strike: $79.98 | $3,470,172.24 |
DisclosureSEC source: 0001179110-19-004731 · edgar.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,388 Underlying: Common shares · 43,388 shares Expires 2029-03-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,462 on April 1, 2020, 14,463 on April 1, 2021, and 14,463 on April 1, 2022. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:24 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
GrantCommon shares without par value | 8,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004731 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,562 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 21:03 UTC |
Bracken Sharon JSenior Vice President
|
Disposition to issuerCommon shares without par value | 38,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004522 · edgar.xml · nonDerivative · entry 1 Bracken Sharon J · CIK 0001710778 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,936 Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 21:32 UTC |
Contreras JaimeSenior Vice President
|
Tax withholdingCommon shares without par value | 385 | $79.94 | $30,776.90 |
DisclosureSEC source: 0001179110-19-004549 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,145 F5 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 21:32 UTC |
Contreras JaimeSenior Vice President
|
GrantCommon shares without par value | 935 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004549 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,530 F4 · shares: This grant represents a restricted stock unit award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting on each anniversary of the grant date. The award includes the right to have stock withheld for tax purposes. F5 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 23:44 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 98 | $79.94 | $7,834.12 |
DisclosureSEC source: 0001179110-19-004612 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 Underlying: Common shares · 98 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 23:44 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 394 | $79.94 | $31,496.36 |
DisclosureSEC source: 0001179110-19-004614 · edgar.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,492 Underlying: Common shares · 394 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 21:10 UTC |
MANNING JOSEPH JSenior Vice President
|
SaleCommon shares without par value | 5,500 | $79.58 | $437,673.50 |
DisclosureSEC source: 0001179110-19-004149 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,529 Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 21:10 UTC |
MANNING JOSEPH JSenior Vice President
|
SaleCommon shares without par value | 113 | $79.57 | $8,991.41 |
DisclosureSEC source: 0001179110-19-004149 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,029 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 294,700 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · derivative · entry 32 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 294,700 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 295,000 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · derivative · entry 31 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 295,000 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 4,700 | $78.19 | $367,493.00 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 30 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688,126 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 100 | $78.87 | $7,886.75 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 29 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,692,826 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 100 | $79.72 | $7,972.00 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 28 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,692,926 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 100 | $78.78 | $7,877.75 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 27 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693,026 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 3,008 | $79.20 | $238,233.60 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 26 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693,126 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 7,092 | $78.90 | $559,558.80 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 25 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,696,134 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 2,649 | $78.90 | $208,992.86 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 24 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,703,226 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 812 | $79.11 | $64,237.32 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 23 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,705,875 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 1,960 | $78.64 | $154,134.40 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 22 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,706,687 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 300 | $78.97 | $23,691.00 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 21 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,708,647 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 123 | $78.41 | $9,643.82 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 20 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,708,947 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 100 | $78.60 | $7,860.00 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 19 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,709,070 Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:29 UTC |
WHITE MILES DDirector · Chairman and CEO
|
SaleCommon shares without par value | 10,908 | $78.06 | $851,423.94 |
DisclosureSEC source: 0001179110-19-004117 · edgar.xml · nonDerivative · entry 18 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,709,170 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.